Assistant Professor, Pathology, University of Michigan Medical School

Pathology

Dr. Scott Tomlins, MD

Scott Tomlins, MD works in the field of Pathology. He studied medicine at University of Michigan Medical School. Scott Tomlins has written publications. He has 44 publications published with PubMed. The lastest publication is: 'Independent Surgical Validation of the New Prostate Cancer Grade Grouping System.' He is registered with Medicare.

Publications

Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation.
Prognostic value of percent Gleason grade 4 at prostate biopsy on predicting prostatectomy pathology and recurrence.
Next-Generation Sequencing of Tubal Intraepithelial Carcinomas.
Reply to Carsten Stephan, Henning Cammann, and Klaus Jung's Letter to the Editor re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PC...
Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology.
Intra-tumor genetic heterogeneity in rectal cancer.
Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.
The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma.
Integrative molecular profiling of routine clinical prostate cancer specimens.
Consequence of the tumor-associated conversion to cyclin D1b.
P3.01Development and validation of a scalable next-generation sequencing system for assessing recurrent somatic alterations in solid tumors.
Histotripsy of the Prostate in a Canine Model: Characterization of Post-Therapy Inflammation and Fibrosis.
Reprint of: The prostate cancer genome: Perspectives and potential.
Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.
Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data.
Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma.
Diffuse large B-cell lymphoma of the prostate.
Determination of Optimum Formalin Fixation Duration for Prostate Needle Biopsies for Immunohistochemistry and Quantum Dot FISH Analysis.
HRAS mutations are frequent in inverted urothelial neoplasms.
Novel RNA Hybridization Method for the In Situ Detection of ETV1, ETV4, and ETV5 Gene Fusions in Prostate Cancer.
Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant pros...
Understanding the Relationship Between Tumor Size, Gland Size, and Disease Aggressiveness in Men With Prostate Cancer.
Aggressive variants of castration-resistant prostate cancer.
Prostate cancer SubtyPINg biomarKers and outcome: is clarity emERGing?
Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer.
HOXB13 G84E-related Familial Prostate Cancers: A Clinical, Histologic, and Molecular Survey.
Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations.
The prostate cancer genome: Perspectives and potential.
At the Intersection of Primary Pulmonary Myxoid Sarcoma and Pulmonary Angiomatoid Fibrous Histiocytoma: Observations from Three New Cases.
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization-a correlative study with urine PCA3 and TMPRSS2-ERG.
Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
Molecular clues assist in the cancer clinic.
Usefulness of a Monoclonal ERG/FLI1 Antibody for Immunohistochemical Discrimination of Ewing Family Tumors.
Identification of Targetable FGFR Gene Fusions in Diverse Cancers.
Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.
Urine PCA3 and TMPRSS2:ERG Using Cancer-specific Markers to Detect Cancer.
Twenty-first century pathology sign-out.
Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.
The mutational landscape of lethal castration-resistant prostate cancer.
The lethal phenotype of cancer: the molecular basis of death due to malignancy.
Independent Surgical Validation of the New Prostate Cancer Grade Grouping System.

Schools

University of Mi Med Sch

Doctors Specialties

Pathology

Accepted Insurances

Education

University of Michigan Hospitals and Health Centers
University of Michigan Medical School

Hospital

University of Michigan Hospitals and Health Centers

Helpful Reviews

Give Anonymous Review

Medicare Facts

National Provider Identifier [NPI]	1164650404
Last Name Of The Provider	TOMLINS
First Name Of The Provider	SCOTT
View All

Similar Doctors

	Dr. Robertson D. Davenport, MD This Doctor is OpenDoctor Recommended.
	Dr. Rebecca C. Hankin, MD
	Dr. Andrew Flint, MD This Doctor is OpenDoctor Recommended.
	Dr. Aleodor A. Andea, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Andrew P. Lieberman, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Joel K. Greenson, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Mohammad Soltani, MD This Doctor is OpenDoctor Recommended.
	Dr. Andrew P. Sciallis, MD This Doctor is OpenDoctor Recommended.
	Brad E. Wasserman